

Biocon Biologics Greece SINGLE MEMBER P.C.**BALANCE SHEET AS AT MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2024</u>
ASSETS		
Non-current assets		
Right to use assets	1	209
Financial assets		
(i) Other financial assets	2	20
Deferred tax asset (net)		15
Total non-current assets		244
Current assets		
Loans and advances		-
Inventories	3	3,036
Financial assets		
(i) Trade receivables	4	5,250
(ii) Cash and cash equivalents	5	74
Other current assets	6	37
Total current assets		8,397
TOTAL		8,641
EQUITY AND LIABILITIES		
Equity		
Equity share capital	7	-
Other equity	8	38
Total equity		38
Non-current liabilities		
Lease liabilities		150
Total current liabilities		150
Current liabilities		
Financial liabilities		
(i) Trade payables	9	8,008
(ii) Lease liabilities		56
Income-tax liability (net)		27
Provisions	10	8
Other current liabilities	11	354
Total current liabilities		8,453
TOTAL		8,641

Biocon Biologics Greece SINGLE MEMBER P.C.
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024
 (All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended March 31, 2024</u>
Income		
Revenue from operations	12	2,544
Total revenue (I)		2,544
Expenses		
Purchases of traded goods	13	1,832
Changes in inventories of traded goods	14	(35)
Employee benefits expense	15	342
Depreciation		9
Finance Costs	16	2
Other expenses	17	344
Total expenses (II)		2,494
Profit before tax		50
Tax expense		
Current tax		27
Deferred Tax		(15)
Total tax expense		12
Profit for the period		38

Biocon Biologics Greece SINGLE MEMBER P.C.**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
I Cash flows from operating activities	
Profit after tax	38
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Depreciation and amortisation (net)	9
Finance costs	2
Tax expense	12
Operating profit before working capital changes	61
Movements in working capital	
(Increase) in trade receivables	(5,255)
(Increase) in trade inventories	(3,036)
(Increase) in loans and advances and other assets	(57)
Increase in trade payable, other liabilities and provisions	8,369
Net cash flow generated from operating activities	82
II Cash flows from investing activities	
Net cash flow from investing activities	-
II Cash flows from financing activities	
Repayment of lease liabilities	(8)
Net cash flow (used) in financing activities	(8)
III Net increase in cash and cash equivalents (I + II)	74
IV Cash and cash equivalents at the end of the year	74
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	74
	74
Total cash and cash equivalents [Refer note 5]	74

Biocon Biologics Greece SINGLE MEMBER P.C.
Notes to financial statements for the period ended March 31, 2024
(All amounts in EUR '000s)

1. Right to use assets

	Vehicles	Total
Gross carrying amount		
At March 31, 2023	-	-
Additions	218	218
At March 31, 2024	218	218
Accumulated depreciation		
At March 31, 2023	-	-
Depreciation for the period	9	9
At March 31, 2024	9	9
Net carrying amount		
At March 31, 2023	-	-
At March 31, 2024	209	209

Biocon Biologics Greece SINGLE MEMBER P.C.**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2024
2. Other non-current financial assets	
VAT receivable	20
	<u>20</u>
3. Inventories	
Finished Goods	3,036
	<u>3,036</u>
4. Trade receivables	
Other Receivables	
Outstanding for a period less than six months from the date they are due for payment	
Unsecured, considered good	5,250
	<u>5,250</u>
5. Cash and cash equivalents	
Balances with banks:	
On current accounts	74
	<u>74</u>
6. Other current assets	
Advance to suppliers	37
	<u>37</u>
	March 31, 2024
7. Share capital	
1 Equity share of EUR 1 each	-
	<u>-</u>
8. Other equity	
Surplus/(deficit) in the statement of profit and loss	
Balance as per the last financial statements	-
Profit / (Loss) for the period	38
Net surplus/(deficit) in the statement of profit and loss	<u>38</u>
9. Trade payables	<u>8,009</u>
10. Provisions	
Current	
Compensated absences	8
	<u>8</u>
11. Other liabilities	
(a) Current liabilities	
Statutory liabilities	354
	<u>354</u>

Biocon Biologics Greece SINGLE MEMBER P.C.**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
12. Revenue from operations	
Sale of Products	
Traded Goods	2,544
	2,544
13. Purchase of traded goods	1,832
	1,832
14. Changes in inventories of traded goods	
Inventory at the beginning of the year	
Traded goods	-
Inventory Transfer during the year	
Traded goods	3,001
Inventory at the end of the year	
Traded goods	3,036
	(35)
15. Employee benefits expense	
Salaries, wages and bonus	342
	342
16. Finance Costs	
Interest on lease obligation	2
	2
17. Other expenses	
Rent	11
Distribution cost	31
Legal and professional fees	61
Travelling and conveyance	30
Sales promotion expenses	205
Printing and stationery	3
Communication expenses	1
Miscellaneous expenses	2
	344